Ovid Therapeutics Inc. is listed today as Ovid Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Ovid Therapeutics Inc.| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|
| Jan 2017 | $26 M | No. 3 | $10 to $50 million | | equity | SEC |
| Aug 2015 | $75 M | No. 2 | $50 to $250 million | | equity | SEC |
| Oct 2014 | $5 M | No. 1 | $2 to $10 million | | equity | SEC |
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Ovid Therapeutics Inc., its revenue in fiscal 2025 came from these business segments: Reportable $7.25 million (100%).
Annual report (SEC XBRL) · Dec 2025
Ovid Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).
SEC Form D · Jan 2017
The industry group it chose in its notices: Other Technology.
SEC Form D · Jan 2017
No products or services of Ovid Therapeutics Inc. are on record.
4 named in official filings. Open an investor to see everything it has backed.
Investors in Ovid Therapeutics Inc.| Investor | Kind | Amount | Round | Role | Source |
|---|
| Jeremy M. Levin | Person | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2017) | SEC Form 3 |
| Matthew During | Person | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2017) | SEC Form 3 |
| Millennium Pharmaceuticals Inc | Company | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Takeda Pharmaceutical Co LTD | Company | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Largest shareholders today
Institutions holding Ovid Therapeutics Inc. shares, as of Sep 30, 2026.
- Janus Henderson Group Ltd.$52 M10.99%
- BlackRock, Inc.$30 M6.38%
- Eventide Asset Management, LLC$29 M6.26%
- Affinity Asset Advisors, LLC$25 M5.38%
- Vanguard Capital Management LLC$19 M4.15%
- Balyasny Asset Management L.P.$18 M3.77%
- Braidwell LP$16 M3.49%
- State Street Corp$15 M3.29%
- Adage Capital Partners GP, L.L.C.$15 M3.27%
- Federated Hermes, Inc.$15 M3.15%
- Silverarc Capital Management, LLC$15 M3.15%
- Ra Capital Management, L.P.$14 M2.97%
- ADAR1 Capital Management, LLC$11 M2.42%
- Geode Capital Management, LLC$11 M2.28%
- Integral Health Asset Management, LLC$9 M1.85%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Ovid Therapeutics Inc.| Name | Role | Named in |
|---|
| Amit E. Rakhit | Executive officer | Jan 2017 |
| Jeremy M. Levin | Executive officer | Jan 2017 |
| Matthew J. During | Executive officer | Jan 2017 |
| Yaron M. Werber | Executive officer | Jan 2017 |
| Bart M. Friedman | Director | Jan 2017 |
| Douglas E. Williams | Director | Jan 2017 |
| Jeremy M. Levin | Director | Jan 2017 |
| Karen E. Bernstein | Director | Jan 2017 |
| Matthew J. During | Director | Jan 2017 |
| Mark M. Feldberg | Director | Mar 2015 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.